A clinical stage gene and cell therapy company
focused on curative intent in solid tumor cancer
focused on curative intent in solid tumor cancer
CHECKPOINT CELL THERAPY
THE NEXT GENERATION OF
CANCER PLATFORM TECHNOLOGY
CISH: a novel immune
checkpoint
checkpoint
T cell genetic engineering
for solid tumor
for solid tumor
T CELL THERAPY IN SOLID TUMOR
THE UNMET MEDICAL NEED
INTIMA BIOSCIENCE CLINICAL TRIAL
Intima Bioscience is conducting a clinical trial initially at the University of Minnesota Masonic Cancer Center with its Molecular and Cell Therapy (MCT) GMP gene and cell therapy manufacturing facility.
Please watch the video below to learn more about our proprietary Checkpoint Cell Therapy, combining two cutting edge therapies for solid tumor cancer in a single clinical trial. A next generation checkpoint inhibitor, CISH with genetically engineered T cell therapy for solid tumors.
A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune Checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Gastro-Intestinal Cancer.
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
PUBLICATIONS
Homology mediated end joining enables efficient non-viral targeted integration of large DNA templates in primary human T cells
Genetic editing of CISH enhances T cell effector programs independently of immune checkpoint cell surface ligand expression
Improved Genome Packaging Efficiency of AAV Vectors Using Rep Hybrids
A Bioinformatic and Empiric Exploration of Prokaryotic Argonautes as Novel Programmable Endonuclease Systems
A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL)
AAV Capsid Chimeras with Enhanced Infectivity reveal a core element in the AAV Genome critical for both Cell Transduction and Capsid Assembly
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade
TECHNOLOGY PLATFORM
T Cells
CISH Checkpoint Target
CRISPR Genetic Engineering
Cell Therapy
3rd generation neoantigen-enriched, genetically-engineered, Tumor Infiltrating Lymphocytes (TIL)
Next Generation Checkpoint
CISH is a novel intra-cellular immune checkpoint and an important negative regulator of T-cell signaling and function
New York City | Cambridge UK
Intima Bioscience, Inc.
3 Columbus Circle, New York, NY 10019, USA
Building 250, Babraham Research Campus, Cambridge, CB22 3AT, UK
